Immuron (IMRN) Non-Current Deferred Tax Liability (2022 - 2024)
Immuron (IMRN) posted quarterly Non-Current Deferred Tax Liability of $28000.0 for Q4 2024, down 80.78% year-on-year from $145663.0 in Q1 2024, and down 80.78% on a QoQ basis from $145663.0 in Q4 2023.
Immuron (IMRN) Non-Current Deferred Tax Liability (2022 - 2024) Analysis & Trends
Immuron (IMRN) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $28000.0 the latest figure, recorded in Q4 2024.
- Quarterly Non-Current Deferred Tax Liability fell 80.78% year-over-year to $28000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $28000.0 (down 80.78% YoY) and the FY2024 annual result came in at $28000.0, down 80.78% from the prior year.
- Non-Current Deferred Tax Liability slipped to $28000.0 in Q4 2024 per IMRN's latest filing, from $145663.0 in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for IMRN reached as high as $698195.0 in Q2 2023 and fell as low as $28000.0 in Q4 2024.
- A 3-year average of $241614.3 and a median of $145663.0 in 2023 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability surged 401.71% — and 2024, when it plunged 80.78%.
- Year by year, Non-Current Deferred Tax Liability stood at $197051.0 in 2022, then retreated by 26.08% to $145663.0 in 2023, then tumbled by 80.78% to $28000.0 in 2024.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $28000.0, $145663.0, and $698195.0 for Q4 2024, Q4 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 28,000.00 |
| Dec 31, 2024 | 28,000.00 |
| Dec 31, 2023 | 145,663.00 |
| Dec 31, 2023 | 145,663.00 |
| Jun 30, 2023 | 698,195.00 |
| Jun 30, 2023 | 698,195.00 |
| Dec 31, 2022 | 197,051.00 |
| Dec 31, 2022 | 197,051.00 |
| Jun 30, 2022 | 139,162.28 |
| Jun 30, 2022 | 139,162.28 |